UTHealth Houston and UTMB will lead IMPACT, an initiative working toward ibogaine-based treatments for addiction and neurological issues. Photo via Pexels.

The Texas Health and Human Services Commission has awarded $50 million to UTHealth Houston in collaboration with The University of Texas Medical Branch at Galveston (UTMB Health) to co-lead a multicenter research trial to evaluate the effect of ibogaine, a powerful psychoactive compound, on patients suffering from addiction, traumatic brain injury and other behavioral health conditions.

The funding will establish a two-year initiative—known as Ibogaine Medicine for PTSD, Addiction, and Cognitive Trauma (IMPACT)—and a consortium of Texas health institutions focused on clinical trials and working toward potential FDA-approved treatments.

The consoritum will also include Texas Tech University, Texas Tech University Health Sciences Center El Paso, The University of Texas at Austin, The University of Texas Health Science Center at San Antonio, The University of Texas at Tyler, The University of Texas Rio Grande Valley, Texas A&M University, The University of North Texas Health Science Center, Baylor College of Medicine and JPS Health Network in Dallas.

Ibogaine is a plant-based, psychoactive substance derived from the iboga shrub. Research suggests that the substance could be used for potential treatment for patients with traumatic brain injuries, which is a leading cause of post-traumatic stress disorders. Ibogaine has also shown potential as a treatment for addiction and other neurological conditions.

UTHealth and partners will focus on ways that ibogaine can treat addiction and associated conditions. Meanwhile, UT Austin and Baylor College of Medicine will concentrate on using it to treat traumatic brain injury, especially in veterans, according to a news release from the institutions.

The consortium will also support drug developers and teaching hospitals to conduct FDA-approved clinical trials. The Texas Health and Human Services Commission will oversee the grant program.

“This landmark clinical trial reflects our unwavering commitment to advancing research that improves lives and delivers the highest standards of care,” Dr. Melina Kibbe, UTHealth Houston president and the Alkek-Williams Distinguished Chair, said in the news release. “By joining forces with outstanding partners across our state, we are building on Texas’ tradition of innovation to ensure patients struggling with addiction and behavioral health conditions have access to the best possible outcomes. Together, we are shaping discoveries that will serve Texans and set a model for the nation.”

The consortium was authorized by the passage of Senate Bill 2308. The bill provides $50 million in state-matching funds for an ibogaine clinical trial managed by a public university in partnership with a drug company and a hospital.

“This is the first major step towards the legislature’s goal of obtaining FDA approval through clinical trials of ibogaine — a potential breakthrough medication that has brought thousands of America’s war-fighters back from the darkest parts of depression, anxiety, PTSD, and chronic addiction,” Texas Rep. Cody Harris added in the release. “I am excited to walk alongside UTHealth Houston and UTMB as these stellar institutions lead the nation in a first-of-its-kind clinical trial in the U.S.”

Recently, the University of Houston also received a $2.6 million gift from the estate of Dr. William A. Gibson to support and expand its opioid addiction research, which includes the development of a fentanyl vaccine that could block the drug's ability to enter the brain. Read more here.

Nai-Hui Chia, an assistant professor of computer science at Rice, was recognized for his research on Hamiltonian simulations, a method for representing the motion of moving particles. Photo via Rice.edu

Houston professor earns Google Scholar award for quantum computing research

recent recognition

A Rice University quantum computer scientist was one of 78 global professors to be presented with a 2023 Google Scholar award, the university announced this month.

Nai-Hui Chia, an assistant professor of computer science at Rice, was recognized for his research on Hamiltonian simulations, a method for representing the motion of moving particles. Chia aims to understand if quantum computers or machines can simulate a "Hamiltonian matrix" with a shorter evolution time.

"We call this fast-forwarding for a Hamiltonian simulation,” Chia says in a statement.

Chia aims to use the funds from Google to discover Hamiltonians that can be fast-forwarded using parallelism or classical computation, according to Rice. He will present his current work on Hamiltonians and their connection to cryptology in July at the 2023 Computational Complexity Conference in Warwick, UK.

The Google Research Scholar program grants funds of up to $60,000 to support professors' research around the world. This year's cohort works in fields ranging from algorithms and optimization to natural language processing to health research.

Three other Texas researchers were awarded funds in the 2023 cohort.

The University of Texas at Austin's Jon Tamir was awarded for his work in applied sciences. Atlas Wang, also from UT, was awarded in the machine learning and data mining category. Shenglong Xu, from Texas A&M University, joined Chia in the quantum computing category.

Tech behemoth Google has awarded funds to several Houston innovators in recent years.

Last summer the company named AnswerBite, Boxes and Ease to its inaugural cohort of the Google for Startups Latino Founders Fund. Selected companies received an equity-free $100,000 investment, as well as programming and support from Google.

In September 2022, ChurchSpace and Enrichly were named part of the Google for Startups Black Founders Fund. The companies also received $100,000 non-dilutive awards along with mentoring and support.

The new endowment will be available beginning in fall 2020. University of Texas at Austin/Facebook

University of Texas at Austin to provide free tuition to families making less than $65,000

higher ed

The University of Texas at Austin is taking a big step to combat the increasing costs of higher education. On July 9, the system's Board of Regents voted to establish a $160 million endowment to help Texas families ease the burden of funding a UT education.

Beginning in fall 2020, the endowment will cover in-state tuition and fees for students from families that earn up to $65,000 a year, or about 8,600 undergraduates a year. (Texas' median income was $59,206 in 2017, according to the most recent available numbers.)

Under the current Texas Advance Commitment, full tuition is only provided to families earning up to $30,000 per year.

Along with covering costs for families making $65,000 or less, the new endowment will provide "tuition support" for families making $125,000 or less, or about 5,700 students.

The $160 million endowment is a distribution of the state's Permanent University Fund, which "includes money from oil and gas royalties earned on state-owned land in West Texas," according to a release.

"There is no greater engine of social and economic mobility than a college degree, and this initiative ensures that more Texans will benefit from a high-quality UT Austin education," said Chancellor James B. Milliken, in a release.

The decision is undoubtedly a banner one for UT President Gregory Fenves, who has spent the majority of his tenure working on affordability issues. In a release, Fenves echoed Milliken, calling the fund an "invest[ment] in the future of our great state."

"I am grateful to the UT System Board of Regents and Chairman Kevin Eltife for prioritizing students and investing in the future of our great state," said Fenves. "This new endowment will go a long way toward making our university affordable for talented Texas students from every background and region."

------

This story originally appeared on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Austin company to bring AI-powered school to The Woodlands

AI education

Austin-based Alpha School, which operates AI-powered private schools, is opening its first Houston-area location in The Woodlands.

The 8,000-square-foot school, scheduled to be ready for the 2026-27 academic year, initially will serve students in kindergarten through eighth grade. Alpha says the school will offer “open workshop spaces and innovative classrooms that support personalized instruction, core academics, leadership development, and real-world life skills.”

Alpha sets aside two hours each school day for the AI-driven, self-paced study of core subjects like math, reading and science. The rest of each school day consists of life-skills workshops focusing on topics such as leadership and financial literacy.

Alpha’s school in The Woodlands has begun accepting applications for the 2026-27 school year. Annual tuition costs $40,000.

“The Woodlands is one of the most dynamic, forward-thinking communities in Texas, and Alpha is proud to bring

an innovative educational model that complements its strong academic foundation,” says Rachel Goodlad, head

of expansion for Alpha.

Founded in 2014, Alpha School combines adaptive technology-driven instruction with immersive life-skills workshops. Its model emphasizes mastery-based learning in core subjects alongside development of communication, critical thinking, financial literacy and leadership skills. It operates more than 15 schools across the country.

Elsewhere in Texas, Alpha operates schools in Austin, Brownsville, Fort Worth and Plano. Alpha also operates 12 Texas Sports Academy campuses in Texas, including locations in Houston, Pearland and Richmond, along with a NextGen Academy esports school in Austin, a school for gifted students in Georgetown, and lower-cost Nova Academy campuses in Austin and Bastrop.

Alpha has fans and critics. While supporters tout students’ high achievement rates, detractors complain about the high tuition and the AI-influenced depersonalization of education.

“Students and our country need to be in relationship with other human beings,” Randi Weingarten, president of the American Federation of Teachers, a teachers union, tells The New York Times. “When you have a school that is strictly AI, it is violating that core precept of the human endeavor and of education.”

Alpha co-founder MacKenzie Price, a podcaster and social media influencer, doesn’t share Weingarten’s views.

“Parents and teachers: We need to embrace this change,” Price wrote after President Trump signed an executive order promoting AI in schools.

The Times notes that Alpha doesn’t employ AI as a tutor or a supplement. Rather, the newspaper says, AI is “the school’s primary educational driver to move students through academic content.”

Houston researcher secures $1.7M to develop drug for aggressive form of breast cancer

cancer research

A University of Houston researcher has joined a $3.2 million effort to develop a new drug designed to attack a cancer-driving protein commonly found in triple-negative breast cancer.

Triple-negative breast cancer (TNBC) is one of the most difficult-to-treat forms of cancer and accounts for 10 percent to 15 percent of all breast cancer cases. The disease gets its name because tumors associated with it test negative for estrogen receptors, progesterone receptors and excess HER2 protein, making it difficult to target. Due to this, TNBC is often treated with general chemotherapy, which can come with negative side effects and drug resistance, according to UH.

UH College of Pharmacy research associate professor Wei Wang is developing a drug that can target the disease more specifically. The drug will target MDM2, a protein often overproduced in TNBC that also contributes to faster tumor growth.

Wang is working on a team led by Wei Li, director of the University of Tennessee Health Science Center College of Pharmacy’s Drug Discovery Center. She has received $1.7 million to support the research.

Wang and UH professor of pharmacology and toxicology Ruiwen Zhang have discovered a compound that can break down MDM2. In early laboratory models, the compound has shown the ability to shrink tumors.

Wang and Zhang will focus on understanding how the treatment works and monitoring its effectiveness in models that closely mirror human disease.

“We will study how the drug targets MDM2 and evaluate the most promising drug candidates to determine effective dosing, understand how the drug behaves in the body, compare it with existing treatments and assess early safety,” Wang said in a news release.

Li’s team at the University of Tennessee will be working on the chemistry and drug design end of the project.

“This work could lead to an entirely new class of therapies for triple-negative breast cancer,” Li added in the release. “We’re hopeful that by directly removing the MDM2 protein from cancer cells, we can help more patients respond to treatment regardless of their tumor type.”